Boston Life Sciences To Present At The Rodman & Renshaw 3rd Annual Global Healthcare Conference
HOPKINTON, Mass., May 8 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. today announced that Peter Savas, Chairman and Chief Executive Officer of Boston Life Sciences, Inc., will be presenting a Company update at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Monday, May 15 from 9:20am - 9:40am EDT (3:20pm - 3:40pm local time). The conference is being held May 15-16 at the Le Meridien Beach Plaza Resort in Monte Carlo, Monaco.
The Boston Life Sciences presentation will be available by webcast. Access to the webcast will be available within the Investor Relations section of the Boston Life Sciences website at http://www.bostonlifesciences.com.
About Boston Life Sciences, Inc.
Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and a Phase II clinical trial for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, a DAT blocker for the treatment of Parkinson's disease and a second generation technetium-based molecular imaging agent for PS and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital of Boston.
ALTROPANE is a registered trademark of Boston Life Sciences, Inc.
Statements in this press release regarding Boston Life Sciences' future financial performance including statements regarding results of operations and net loss, and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Boston Life Sciences' actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including those factors contained in Boston Life Sciences' Annual Report on Form 10-K for the year ended December 31, 2005 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. Forward-looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "should", "will", and "would" or similar words. Boston Life Sciences assumes no obligations to update the information in this press release.
Contact: Sharon Correia -- 508-497-2360 ext 224
Boston Life Sciences, Inc. scorreia@bostonlifesciences.com
Boston Life Sciences, Inc.
CONTACT: Sharon Correia, Boston Life Sciences, Inc., +1-508-497-2360, ext.224, scorreia@bostonlifesciences.com
Web site: http://www.bostonlifesciences.com//